The Development of BTK Degraders for Patients With Relapsed CLL

H&O What are Bruton tyrosine kinase (BTK) degraders, and how do they differ from BTK inhibitors? AD BTK degraders are from a new class of molecules, […]

The Use of Fixed-Dose Regimens in Chronic Lymphocytic Leukemia

H&O What fixed-dose regimens are in use in chronic lymphocytic leukemia (CLL)? AK Fixed-duration regimens have been used for a long time in patients with CLL. […]

Is MRD Testing Ready for General Use in Chronic Lymphocytic Leukemia?

H&O What are the potential uses of measurable residual disease (MRD) testing in patients with chronic lymphocytic leukemia (CLL)? CO The most important use of MRD […]

Choosing Between CAR T-Cell Therapy and Pirtobrutinib in Double-Refractory CLL

H&O What does it mean to have double-refractory chronic lymphocytic leukemia (CLL)? KR We do not have a definition that everyone in the field agrees with […]

Doublet vs Triplet Combinations for Frontline Treatment of Chronic Lymphocytic Leukemia

H&O What are the advantages of doublet combinations over single-agent Bruton tyrosine kinase (BTK) inhibitor therapy in the frontline therapy of chronic lymphocytic leukemia (CLL)? NJ […]

The Approval of Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia

H&O When did lisocabtagene maraleucel first receive approval? WW The US Food and Drug Administration (FDA) first approved lisocabtagene maraleucel (liso-cel; Breyanzi, Bristol Myers Squibb) on […]

Pirtobrutinib in Relapsed or Refractory CLL and SLL

H&O What are the mechanisms of action of pirtobrutinib and other Bruton tyrosine kinase (BTK) inhibitors? JW All of the currently available BTK inhibitors work by […]

Six-Year Update of the ELEVATE-TN Study on Acalabrutinib

H&O Could you describe the impetus for and design of the ELEVATE-TN trial? JS The ELEVATE-TN study was conducted to seek regulatory authorization for acalabrutinib (Calquence, […]

Genomic Risk Stratification in Chronic Lymphocytic Leukemia

H&O Which patients with chronic lymphocytic leukemia (CLL) require treatment? AW A substantial proportion of patients with CLL can go for decades with no need for […]

Preventing Infectious Complications in Chronic Lymphocytic Leukemia

H&O What causes the elevated risk of infections in patients with chronic lymphocytic leukemia (CLL)? CS Immunologic defects in patients with CLL are caused by the […]

Management of Richter Transformation

H&O How often does chronic lymphocytic leukemia (CLL) transform into aggressive lymphoma? MD Transformation of CLL into aggressive lymphoma, known as Richter transformation (RT), is relatively […]

Managing CLL That Has Progressed After BTK Inhibition

H&O When patients with chronic lymphocytic leukemia (CLL) progress while on Bruton tyrosine kinase (BTK) inhibitor therapy, what is your next therapy of choice? LR Because […]

Is There Still a Role for PI3K Inhibitors in CLL?

H&O What did the DUO trial find regarding the use of duvelisib in previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)? IWF The […]

Addressing Cardiovascular Complications of BTK Inhibitors

H&O What are the specific cardiovascular complications that are associated with Bruton tyrosine kinase (BTK) inhibitors? JM Many cancer drugs have adverse effects on the heart […]

The Use of Zanubrutinib in Chronic Lymphocytic Leukemia

H&O What makes the various Bruton tyrosine kinase (BTK) inhibitors different from one another? DB A variety of BTK inhibitors have been approved for use in […]

The Clinical Importance of Prognostic Markers in CLL

H&O How has the role of prognostic markers in chronic lymphocytic leukemia (CLL) changed with the transition from standard chemoimmunotherapy drugs to targeted agents? JA Since […]

Clinical Use of Measurable Residual Disease in CLL

H&O What are some of the limitations of the International Workshop on CLL (iwCLL) response criteria for chronic lymphocytic leukemia (CLL) in the era of novel […]

The Use of Chimeric Antigen T-Cell Therapy in Chronic Lymphocytic Leukemia

H&O What options are available for patients with chronic lymphocytic leukemia (CLL) that is refractory to Bruton tyrosine kinase (BTK) inhibitors and venetoclax? TS This is […]

The Emerging Role of Pirtobrutinib in Chronic Lymphocytic Leukemia

H&O How has the advent of Bruton tyrosine kinase (BTK) inhibitors impacted the treatment of patients with chronic lymphocytic leukemia (CLL)? NL The advent of BTK […]

The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Abstract: Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods […]